ALXN210

FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
CP Wire
Mon, 08/20/18 - 11:40 am
Alexion Pharmaceuticals
Alexion
FDA
ALXN210
PNH
paroxysmal nocturnal hemoglobinuria